[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611293":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":86,"collaborators":25,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":25,"eligibilityCriteria":93,"healthyVolunteers":90,"sex":94,"minAge":95,"maxAge":25,"enrollmentInfo":96,"targetDuration":25,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Alcon Research","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1: FID123440, then FID123437","EXPERIMENTAL","One drop of FID123440 test formulation in each eye in Period 1, followed by 1 drop of FID123437 test formulation in each eye in Period 2 as randomized. Each period is 1 day long with at least 2 calendar days separating the periods.",[13,14],"Other: FID123440 test formulation","Other: FID123437 test formulation",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence 2: FID123437, then FID123440","One drop of FID123437 test formulation in each eye in Period 1, followed by 1 drop of FID123440 test formulation in each eye in Period 2 as randomized. Each period is 1 day long with at least 2 calendar days separating the periods.",[14,13],[20,26,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"OTHER","FID123440 test formulation","Investigational product",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"FID123437 test formulation",[9,16],{"type":21,"name":22,"description":23,"armGroupLabels":30,"otherNames":25},[16],[32],{"name":33,"affiliation":34,"role":35},"Clinical Trial Lead, Dry Eye","Alcon Research, LLC","STUDY_DIRECTOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":25,"email":41},"Alcon Call Center","CONTACT","1-888-451-3937","alcon.medinfo@alcon.com",[43,57,67,77],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":25},"School of Optometry and Vision","RECRUITING","Sydney","New South Wales","2052","Australia","AU",{"type":52,"coordinates":53},"Point",[54,55],151.20732,-33.86785,{"lat":55,"lon":54},{"facility":58,"status":45,"city":59,"state":60,"zip":61,"country":49,"countryCode":50,"cosmosGeoPoint":62,"geoPoint":66,"contacts":25},"Ophthalmic Trials Australia","Teneriffe","Queensland","4005",{"type":52,"coordinates":63},[64,65],153.04696,-27.45587,{"lat":65,"lon":64},{"facility":68,"status":45,"city":69,"state":70,"zip":71,"country":49,"countryCode":50,"cosmosGeoPoint":72,"geoPoint":76,"contacts":25},"The University of Melbourne, Department of Optometry and Vision Science","Carlton","Victoria","3053",{"type":52,"coordinates":73},[74,75],144.96667,-37.8,{"lat":75,"lon":74},{"facility":78,"status":45,"city":79,"state":70,"zip":80,"country":49,"countryCode":50,"cosmosGeoPoint":81,"geoPoint":85,"contacts":25},"Deakin Collaborative Eye Care Clinic, Deakin University","Waurn Ponds","3216",{"type":52,"coordinates":82},[83,84],144.28333,-38.21667,{"lat":84,"lon":83},{"type":87,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100611293","an-evaluation-of-the-safety-and-tolerability-of-ocular-lubricants-100611293",false,"NCT07238699","An Evaluation of the Safety and Tolerability of Ocular Lubricants","Inclusion Criteria:\n\n* Subject must be willing and able to understand and sign an ethics committee approved informed consent form.\n* Subject must be willing and able to attend all study visits as required by the protocol.\n* Subject must exhibit symptoms of dry eye at the Screening Visit.\n* Subject must currently use artificial tears.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Has any known active ocular disease and\u002For infection.\n* Has any known infection or inflammation that requires treatment or has a systemic condition that, in the opinion of the investigator, may affect a study outcome variable.\n* Any ocular injury to either eye in the 12 weeks prior to screening.\n* Current wearer of contact lenses or has a history of contact lens wear within the previous 1 month.\n* Other protocol-defined exclusion criteria may apply.","ALL","18 Years",{"count":97,"type":98},148,"ESTIMATED","INTERVENTIONAL",[101],"NA","The purpose of this study is to evaluate the safety and tolerability of two new artificial tear formulations in subjects with moderate dry eye disease.",[104],"Dry Eye Disease",[106,107,108],"Itchy eyes","Stinging eyes","Scratchy eyes","2026-03-09",{"date":111,"type":112},"2026-03-11","ACTUAL",{"date":114,"type":112},"2026-03-04",{"date":116,"type":98},"2026-08",{"name":5,"class":6},4]